Testing a new drug combo for advanced lung cancer with COPD
Part of Lungs & breathing clinical trials.
This trial tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy and inhaled steroids helps people with advanced lung cancer who also have COPD. The goal is to see if this combination improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have stage IIIB or IV squamous non-small cell lung cancer that has not been treated before for advanced disease.
- You have moderate to severe COPD that is stable, with a certain level of eosinophils (a type of white blood cell) in your blood.
- Your cancer does not have certain gene changes (like EGFR or ALK).
- You are well enough to have daily activities (ECOG 0-2).
- You have not used oral or IV steroids for any reason in the last month.
- You are not pregnant or nursing, and you are not in another trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
This study tests a new combination treatment (BL-B01D1 plus a bispecific antibody) against a standard chemotherapy-plus-bispecific-antibody combo for people with advanced squamous non-small cell lung cancer who have not yet received any treatment. It aims to see if the new drug combo works better at shrinking tumors or delaying cancer growth.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
This trial tests a new drug (tarlatamab) combined with chemotherapy and immunotherapy for people whose lung cancer has changed from one type (adenocarcinoma) to small cell lung cancer after treatment with EGFR targeted therapy. The goal is to see if this combination is safe and works well.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests adding a new drug, iadademstat, to standard immunotherapy drugs (atezolizumab or durvalumab) for people with small cell lung cancer that responded to initial treatment. The goal is to see if this combination works better at preventing cancer from returning.
Hear when a new COPD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.